Unlike most other methods, PGT[A]Seq combines two distinct pieces of information to provide unparalleled accuracy. The test simultaneously assesses the quantity of DNA at numerous sites on each chromosome using an advanced next generation sequencing method and combines this information with analysis of DNA sequence variations, which provide an independent evaluation of chromosome copy number.
Juno uses a unique PGT[A]Seq methodology, which is the only method in the world to have successfully demonstrated clinical validity in a non-selectin study.
Our PGT[A]Seq strategy employs the latest next-generation sequencing methods, increasing the quality of the data obtained and yielding results of unparalleled accuracy.
Neo24 It is a non-invasive prenatal test, performed with maternal blood, completely safe for the mother and her unborn child. We analyze the 24 chromosomes for the peace of mind of future mothers.
Enables established pregnancies (from 10 weeks of gestation) to be assessed for certain chromosome abnormalities that can lead to late miscarriages or the birth of a child with serious congenital abnormalities.
Neo24 test results are usually available within 5 days of Juno receiving the sample of maternal blood (although up to 10 days may be required)
Juno Genetics harnesses the power of the very latest DNA sequencing technologies to deliver a best-in-class test for chromosome abnormalities, called PGT[A]seq. Not only does PGT[A]seq measure the amount of DNA from each chromosome with unprecedented accuracy, allowing the number of copies of each chromosome to be determined in the embryo biopsy specimen, but it also detects thousands of variations in the sequence of the DNA from the embryo (known as polymorphisms). Juno was one of the first laboratories in the world to add polymorphism analysis to a PGT-A test. The extra information provided by DNA polymorphisms allows detection of important chromosome abnormalities that are invisible to other PGT-A methods, including triploidy, a common cause of miscarriage. Clinical studies have shown that the Juno PGT[A]seq method succeeds in providing valuable predictive information about an embryo’s capacity to produce a healthy birth, helping to avoid the transfer of abnormal embryos, which will fail to implant, miscarry or produce children affected by chromosomal abnormalities.
Many of the advanced PGT methods used by Juno Genetics are available nowhere else in the world. Consequently, it is necessary to send samples to the Juno laboratory (in Oxford, UK) in order to access the tests. In most cases, the time required for the shipping of samples, and for the complex laboratory procedures, means that embryos must be cryopreserved (vitrified) while the test is carried out. Embryos can usually be thawed and transferred during the following cycle.